Therapeutic treatments potentially mediated by melatonin receptors: Potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapy

Journal of Pineal Research

Volumn 41, Issue 4, 2006, Pages 297-305

  Witt Enderby, Paula A ^a   Radio, Nicholas M ^a   Doctor, John S ^a   Davis, Vicki L ^a  

^a DUQUESNE UNIVERSITY   (United States)

Author keywords

Cancer; Hormone replacement therapy; Melatonin; Melatonin receptors; Osteoporosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ESTROGEN; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; PARATHYROID HORMONE[1-34]; TAMOXIFEN;

ADJUVANT THERAPY; BONE DEVELOPMENT; BONE MINERALIZATION; BONE REMODELING; BREAST CANCER; CANCER; CANCER PREVENTION; CANCER RISK; CELL DIFFERENTIATION; CELL PROLIFERATION; CIRCADIAN RHYTHM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENDOMETRIUM CANCER; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; IDIOPATHIC SCOLIOSIS; MELANOMA; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; PINEAL BODY; PINEALECTOMY; PROTEIN EXPRESSION; SHORT SURVEY; SLEEP DISORDER;

ANIMALS; CHEMOTHERAPY, ADJUVANT; HUMANS; MELATONIN; NEOPLASMS; OSTEOPOROSIS; RECEPTORS, MELATONIN; SIGNAL TRANSDUCTION;

EID: 33749317848     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2006.00369.x     Document Type: Short Survey

References (104)

1. TOUITOU Y. Human aging and melatonin. Clinical relevance. Exp Gerontol 2001; 36:1083-1100.
2. NAJI L, CARRILLO-VICO A, GUERRERO JM, CALVO JR. Expression of membrane and nuclear melatonin receptors in mouse peripheral organs. Life Sci 2004; 74:2227-2236.
3. DELAGRANGE P, ATKINSON J, BOUTIN JA et al. Therapeutic perspectives for melatonin agonists and antagonists. J Neuroendocrinol 2003; 15:442-448.
4. BUBENIK GA. Gastrointestinal melatonin: localization, function, and clinical relevance. Dig Dis Sci 2002; 47:2336-2348.
5. CARRILLO-VICO A, GARCIA-PERGANEDA A, NAJI L, CALVO JR, ROMERO MP, GUERRERO JM. Expression of membrane and nuclear melatonin receptor mRNA and protein in the mouse immune system. Cell Mol Life Sci 2003; 60:2272-2278.
6. KARASEK M. Melatonin, human aging, and age-related diseases. Exp Gerontol 2004; 39:1723-1729.
7. CHUCHAROEN P, CHETSAWANG B, SRIKIATKHACHORN A, GOVITRAPONG P. Melatonin receptor expression in rat cerebral artery. Neurosci Lett 2003; 341:259-261.
8. HARROD CG, BENDOK BR, HUNT BATJER H. Interactions between melatonin and estrogen may regulate cerebrovascular function in women: clinical implications for the effective use of HRT during menopause and aging. Med Hypotheses 2005;64:725-735.
9. MASANA MI, DOOLEN S, ERSAHIN C et al. MT(2) melatonin receptors are present and functional in rat caudal artery. J Pharmacol Exp Ther 2002; 302:1295-1302.
10. TOMAS-ZAPICO C, COTO-MONTES A. A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes. J Pineal Res 2005; 39:99-104.
11. RODRIGUEZ C, MAYO JC, SAINZ RM et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004; 36:1-9.
12. VIJAYALAXMI, REITER RJ, TAN DX, HERMAN TS, THOMAS CR Jr. Melatonin as a radioprotective agent: a review. Int J Radiat Oncol Biol Phys 2004; 59:639-653.
13. ZHAO H, POON AM, PANG SF. Pharmacological characterization, molecular subtyping, and autoradiographic localization of putative melatonin receptors in uterine endometrium of estrous rats. Life Sci 2000; 66:1581-1591.
14. SOARES JR JM, MASANA MI, ERSAHIN C, DUBOCOVICH ML. Functional melatonin receptors in rat ovaries at various stages of the estrous cycle. J Pharmacol Exp Ther 2003; 306:694-702.
15. CLEMENS JW, JARZYNKA MJ, WITT-ENDERBY PA. Downregulation of mt1 melatonin receptors in rat ovary following estrogen exposure. Life Sci 2001; 69:27-35.
16. PINTOR J, PELAEZ T, HOYLE CH, PERAL A. Ocular hypotensive effects of melatonin receptor agonists in the rabbit: further evidence for an MT3 receptor. Br J Pharmacol 2003; 138:831-836.
17. CARDINALI DP, LADIZESKY MG, BOGGIO V, CUTRERA RA, MAUTALEN C. Melatonin effects on bone: experimental facts and clinical perspectives. J Pineal Res 2003; 34:81-87.
18. TSUCHIYA Y, NISHIDA E. Mammalian cultured cells as a model system of peripheral circadian clocks. J Biochem (Tokyo) 2003; 134:785-790.
19. REPPERT SM, WEAVER DR, EBISAWA T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 1994; 13:1177-1185.
20. REPPERT SM, GODSON C, MAHLE CD, WEAVER DR, SLAUGENHAUPT SA, GUSELLA JF. Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc Natl Acad Sci U S A 1995; 92:8734-8738.
21. ANISIMOV SV, BOHELER KR, ANISIMOV VN. Microarray technology in studying the effect of melatonin on gene expression in the mouse heart. Dokl Biol Sci 2002; 383:90-95.
22. BAILEY MJ, BEREMAND PD, HAMMER R, BELL-PEDERSEN D, THOMAS TL, CASSONE VM. Transcriptional profiling of the chick pineal gland, a photoreceptive circadian oscillator and pacemaker. Mol Endocrinol 2003; 17:2084-2095.
23. BAILEY MJ, BEREMAND PD, HAMMER R, REIDEL E, THOMAS TL, CASSONE VM. Transcriptional profiling of circadian patterns of mRNA expression in the chick retina. J Biol Chem 2004; 279:52247-52254.
24. WITT-ENDERBY PA, BENNETT J, JARZYNKA MJ, FIRESTINE S, MELAN MA. Melatonin receptors and their regulation: biochemical and structural mechanisms. Life Sci 2003; 72:2183-2198.
25. SANCHEZ-BARCELO EJ, COS S, MEDIAVILLA D, MARTINEZ-CAMPA C, GONZALEZ A, ALONSO-GONZALEZ C. Melatonin-estrogen interactions in breast cancer. J Pineal Res 2005;38:217-222.
26. NOSJEAN O, FERRO M, COGE F et al. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem 2000; 275:31311-31317.
27. LEWY AJ, AHMED S, JACKSON JM, SACK RL. Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int 1992; 9:380-392.
28. OSTROWSKA Z, KOS-KUDLA B, MAREK B, KAJDANIUK D. Influence of lighting conditions on daily rhythm of bone metabolism in rats and possible involvement of melatonin and other hormones in this process. Endocr Regul 2003; 37:163-174.
29. BLASK DE, SAUER LA, DAUCHY RT. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem 2002;2:113-132.
30. POIREL VJ, MASSON-PEVET M, PEVET P, GAUER F. MT1 melatonin receptor mRNA expression exhibits a circadian variation in the rat suprachiasmatic nuclei. Brain Res 2002;946:64-71.
31. RUTTER J, REICK M, MCKNIGHT SL. Metabolism and the control of circadian rhythms. Annu Rev Biochem 2002;71:307-331.
32. MAGRI F, SARRA S, CINCHETTI W et al. Qualitative and quantitative changes of melatonin levels in physiological and pathological aging and in centenarians. J Pineal Res 2004;36:256-261.
33. SCHMIDT RE, DORSEY DA, PARVIN CA, BEAUDET LN. Sympathetic neuroaxonal dystrophy in the aged rat pineal gland. Neurobiol Aging 2005.
34. OSTROWSKA Z, KOS-KUDLA B, NOWAK M et al. The relationship between bone metabolism, melatonin and other hormones in sham-operated and pinealectomized rats. Endocr Regul 2003; 37:211-224.
35. ABDEL-WANIS ME, KAWAHARA N. Skeletal disorders associated with skin pigmentation: a role of melatonin? Med Hypotheses 2003; 61:640-642.
36. TURGUT M, USLU S, UYSAL A, YURTSEVEN ME, USTUN H. Changes in vascularity of cartilage endplate of degenerated intervertebral discs in response to melatonin administration in rats. Neurosurg Rev 2003; 26:133-138.
37. TURGUT M, KAPLAN S, TURGUT AT et al. Morphological, stereological and radiological changes in pinealectomized chicken cervical vertebrae. J Pineal Res 2005; 39:392-399.
38. INOH H, KAWAKAMI N, MATSUYAMA Y et al. Correlation between the age of pinealectomy and the development of scoliosis in chickens. Spine 2001; 26:1014-1021.
39. FJELLDAL PG, GROTMOL S, KRYVI H et al. Pinealectomy induces malformation of the spine and reduces the mechanical strength of the vertebrae in Atlantic salmon, Salmo salar. J Pineal Res 2004; 36:132-139.
40. MOREAU A, WANG DAS, FORGET S et al. Melatonin signaling dysfunction in adolescent idiopathic scoliosis. Spine 2004;29:1772-1781.
41. TAN DX, MANCHESTER LC, REITER RJ et al. Identification of highly elevated levels of melatonin in bone marrow: its origin and significance. Biochim Biophys Acta 1999; 1472:206-214.
42. RADIO NM, DOCTOR JS, WITT-ENDERBY PA. Melatonin enhances alkaline phosphatase activity in differentiating human adult mesenchymal stem cells grown in osteogenic medium via MT2 melatonin receptors and the MEK/ERK (1/2) signaling cascade. J Pineal Res 2006; 40:332-342.
43. MORCUENDE JA, MINHAS R, DOLAN L et al. Allelic variants of human melatonin 1A receptor in patients with familial adolescent idiopathic scoliosis. Spine 2003; 28:2025-2028; discussion 2029.
44. OYAMA J, MURAI I, KANAZAWA K, MACHIDA M. Bipedal ambulation induces experimental scoliosis in C57BL/6J mice with reduced plasma and pineal melatonin levels. J Pineal Res 2006; 40:219-224.
45. CHEUNG KM, WANG T, POON AM et al. The effect of pinealectomy on scoliosis development in young nonhuman primates. Spine 2005; 30:2009-2013.
46. SIMMONS DJ, GRYNPASS MD. Mechanisms of Bone Formation In vivo. The Telford Press, Caldwell, 1990.
47. DUCY P, SCHINKE T, KARSENTY G. The osteoblast: a sophisticated fibroblast under central surveillance. Science 2000; 289:1501-1504.
48. SUZUKI N, HATTORI A. Melatonin suppresses osteoclastic and osteoblastic activities in the scales of goldfish. J Pineal Res 2002; 33:253-258.
49. KOYAMA H, NAKADE O, TAKADA Y, KAKU T, LAU KH. Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation. J Bone Miner Res 2002; 17:1219-1229.
50. ROTH JA, KIM BG, LIN WL, CHO MI. Melatonin promotes osteoblast differentiation and bone formation. J Biol Chem 1999; 274:22041-22047.
51. LADIZESKY MG, BOGGIO V, ALBORNOZ LE, CASTRILLON PO, MAUTALEN C, CARDINALI DP. Melatonin increases oestradiol-induced bone formation in ovariectomized rats. J Pineal Res 2003; 34:143-151.
52. NAKADE O, KOYAMA H, ARIJI H, YAJIMA A, KAKU T. Melatonin stimulates proliferation and type I collagen synthesis in human bone cells in vitro. J Pineal Res 1999; 27:106-110.
53. SUZUKI A, PALMER G, BONJOUR JP, CAVERZASIO J. Regulation of alkaline phosphatase activity by p38 MAP kinase in response to activation of Gi protein-coupled receptors by epinephrine in osteoblast-like cells. Endocrinology 1999;140:3177-3182.
54. SUZUKI A, GUICHEUX J, PALMER G et al. Evidence for a role of p38 MAP kinase in expression of alkaline phosphatase during osteoblastic cell differentiation. Bone 2002; 30:91-98.
55. RAWADI G, FERRER C, SPINELLA-JAEGLE S, ROMAN-ROMAN S, BOUALI Y, BARON R. 1-(5-oxohexyl)-3,7-Dimethylxanthine, a phosphodiesterase inhibitor, activates MAPK cascades and promotes osteoblast differentiation by a mechanism independent of PKA activation (pentoxifylline promotes osteoblast differentiation). Endocrinology 2001;142:4673-4682.
56. XIAO G, JIANG D, THOMAS P et al. MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. J Biol Chem 2000; 275:4453-4459.
57. FUJITA T, MEGURO T, FUKUYAMA R, NAKAMUTA H, KOIDA M. New signaling pathway for parathyroid hormone and cyclic AMP action on extracellular-regulated kinase and cell proliferation in bone cells. Checkpoint of modulation by cyclic AMP. J Biol Chem 2002; 277:22191-22200.
58. ROHR UD, HEROLD J. Melatonin deficiencies in women. Maturitas 2002; 41(Suppl. 1): S85-S104.
59. SCHERNHAMMER ES, LADEN F, SPEIZER FE et al. Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. J Natl Cancer Inst 2001; 93:1563-1568.
60. MEGDAL SP, KROENKE CH, LADEN F, PUKKALA E, SCHERNHAMMER ES. Night work and breast cancer risk: a systematic review and meta-analysis. Eur J Cancer 2005; 41:2023-2032.
61. BLASK DE, BRAINARD GC, DAUCHY RT et al. Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res 2005; 65:11174-11184.
62. COS S, SANCHEZ-BARCELO EJ. Melatonin and mammary pathological growth. Front Neuroendocrinol 2000; 21:133-170.
63. MAZZOCCOLI G, CARUGHI S, DE CATA A, LA VIOLA M, VENDEMIALE G. Melatonin and cortisol serum levels in lung cancer patients at different stages of disease. Med Sci Monit 2005; 11:CR284-288.
64. KARASEK M, KOWALSKI AJ, SUZIN J, ZYLINSKA K, SWIETOSLAWSKI J. Serum melatonin circadian profiles in women suffering from cervical cancer. J Pineal Res 2005; 39:73-76.
65. LEVIN RD, DAEHLER MA, GRUTSCH JF et al. Circadian function in patients with advanced non-small-cell lung cancer. Br J Cancer 2005; 93:1202-1208.
66. MAESTRONI GJ, CONTI A. Melatonin in human breast cancer tissue: association with nuclear grade and estrogen receptor status. Lab Invest 1996; 75:557-561.
67. LISSONI P, PAOLOROSSI F, TANCINI G et al. A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients. Br J Cancer 1996; 74:1466-1468.
68. TRAVIS RC, ALLEN DS, FENTIMAN IS, KEY TJ. Melatonin and breast cancer: a prospective study. J Natl Cancer Inst 2004; 96:475-482.
69. VIJAYALAXMI, THOMAS CR JR, REITER RJ, HERMAN TS. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 2002; 20:2575-2601.
70. SCHERNHAMMER ES, HANKINSON SE. Urinary melatonin levels and breast cancer risk. J Natl Cancer Inst 2005; 97:1084-1087.
71. CANAPLE L, KAKIZAWA T, LAUDET V. The days and nights of cancer cells. Cancer Res 2003; 63:7545-7552.
72. ZHU Y, BROWN HN, ZHANG Y, STEVENS RG, ZHENG T. Period3 structural variation: a circadian biomarker associated with breast cancer in young women. Cancer Epidemiol Biomarkers Prev 2005; 14:268-270.
73. COS S, SANCHEZ-BARCELO EJ. Melatonin, experimental basis for a possible application in breast cancer prevention and treatment. Histol Histopathol 2000; 15:637-647.
74. LENOIR V, DE JONAGE-CANONICO MB, PERRIN MH, MARTIN A, SCHOLLER R, KERDELHUE B. Preventive and curative effect of melatonin on mammary carcinogenesis induced by dimethylbenz[a]anthracene in the female Sprague-Dawley rat. Breast Cancer Res 2005; 7:R470-R476.
75. COS S, BLASK DE. Melatonin modulates growth factor activity in MCF-7 human breast cancer cells. J Pineal Res 1994; 17:25-32.
76. LEON-BLANCO MM, GUERRERO JM, REITER RJ, CALVO JR, POZO D. Melatonin inhibits telomerase activity in the MCF-7 tumor cell line both in vivo and in vitro. J Pineal Res 2003; 35:204-211.
77. BATURIN DA, ALIMOVA IN, ANISIMOV VN et al. The effect of light regimen and melatonin on the development of spontaneous mammary tumors in HER-2/neu transgenic mice is related to a downregulation of HER-2/neu gene expression. Neuro Endocrinol Lett 2001; 22:441-447.
78. ANISIMOV VN, ALIMOVA IN, BATURIN DA et al. The effect of melatonin treatment regimen on mammary adenocarcinoma development in HER-2/neu transgenic mice. Int J Cancer 2003;103:300-305.
79. RAO GN, NEY E, HERBERT RA. Effect of melatonin and linolenic acid on mammary cancer in transgenic mice with c-neu breast cancer oncogene. Breast Cancer Res Treat 2000; 64:287-296.
80. DAI J, INSCHO EW, YUAN L, HILL SM. Modulation of intracellular calcium and calmodulin by melatonin in MCF-7 human breast cancer cells. J Pineal Res 2002; 32:112-119.
81. BORDT SL, MCKEON RM, LI PK, WITT-ENDERBY PA, MELAN MA. N1E-115 mouse neuroblastoma cells express MT1 melatonin receptors and produce neurites in response to melatonin. Biochim Biophys Acta 2001; 1499:257-264.
82. DILLON DC, EASLEY SE, ASCH BB et al. Differential expression of high-affinity melatonin receptors (MT1) in normal and malignant human breast tissue. Am J Clin Pathol 2002; 118:451-458.
83. SHIU SY, LAW IC, LAU KW, TAM PC, YIP AW, NG WT. Melatonin slowed the early biochemical progression of hormone-refractory prostate cancer in a patient whose prostate tumor tissue expressed MT1 receptor subtype. J Pineal Res 2003; 35:177-182.
84. YUAN L, COLLINS AR, DAI J, DUBOCOVICH ML, HILL SM. MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Mol Cell Endocrinol 2002; 192:147-156.
85. COLLINS A, YUAN L, KIEFER TL, CHENG Q, LAI L, HILL SM. Overexpression of the MT1 melatonin receptor in MCF-7 human breast cancer cells inhibits mammary tumor formation in nude mice. Cancer Lett 2003; 189:49-57.
86. KADEKARO AL, ANDRADE LN, FLOETER-WINTER LM et al. MT-1 melatonin receptor expression increases the antiproliferative effect of melatonin on S-91 murine melanoma cells. J Pineal Res 2004; 36:204-211.
87. JONES MP, MELAN MA, WITT-ENDERBY PA. Melatonin decreases cell proliferation and transformation in a melatonin receptor-dependent manner. Cancer Lett 2000; 151:133-143.
88. VIEIRA DE SOUZA A, VISCONTI MA, DE LAURO CASTRUCCI AM. Melatonin biological activity and binding sites in human melanoma cells. J Pineal Res 2003; 34:242-248.
89. KOBAYASHI Y, ITOH MT, KONDO H et al. Melatonin binding sites in estrogen receptor-positive cells derived from human endometrial cancer. J Pineal Res 2003; 35:71-74.
90. LEON-BLANCO MM, GUERRERO JM, REITER RJ, POZO D. RNA expression of human telomerase subunits TR and TERT is differentially affected by melatonin receptor agonists in the MCF-7 tumor cell line. Cancer Lett 2004; 216:73-80.
91. CARRILLO-VICO A, GARCIA-MAURINO S, CALVO JR, GUERRERO JM. Melatonin counteracts the inhibitory effect of PGE2 on IL-2 production in human lymphocytes via its mt1 membrane receptor. FASEB J 2003; 17:755-757.
92. RATO AG, PEDRERO JG, MARTINEZ MA, DEL RIO B, LAZO PS, RAMOS S. Melatonin blocks the activation of estrogen receptor for DNA binding. FASEB J 1999; 13:857-868.
93. KIEFER T, RAM PT, YUAN L, HILL SM. Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells. Breast Cancer Res Treat 2002; 71:37-45.
94. DEL RIO B, GARCIA PEDRERO JM, MARTINEZ-CAMPA C, ZUAZUA P, LAZO PS, RAMOS S. Melatonin, an endogenous-specific inhibitor of estrogen receptor alpha via calmodulin. J Biol Chem 2004; 279:38294-38302.
95. CINI G, NERI B, PACINI A et al. Antiproliferative activity of melatonin by transcriptional inhibition of cyclin D1 expression: a molecular basis for melatonin-induced oncostatic effects. J Pineal Res 2005; 39:12-20.
96. LISSONI P, CHILELLI M, VILLA S, CERIZZA L, TANCINI G. Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. J Pineal Res 2003; 35:12-15.
97. MILLS E, WU P, SEELY D, GUYATT G. Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. J Pineal Res 2005; 39:360-366.
98. REITER RJ, TAN DX, SAINZ RM, MAYO JC, LOPEZ-BURILLO S. Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol 2002; 54:1299-1321.
99. YAVUZ MN, YAVUZ AA, ULKU C et al. Protective effect of melatonin against fractionated irradiation-induced epiphyseal injury in a weanling rat model. J Pineal Res 2003; 35:288-294.
100. ANWAR MM, MAHFOUZ HA, SAYED AS. Potential protective effects of melatonin on bone marrow of rats exposed to cytotoxic drugs. Comp Biochem Physiol A Mol Integr Physiol 1998; 119:493-501.
101. BARTSCH H, BARTSCH C, DEERBERG F, MECKE D. Seasonal rhythms of 6-sulphatoxymelatonin (aMT6s) excretion in female rats are abolished by growth of malignant tumors. J Pineal Res 2001; 31:57-61.
102. YOU S, WOOD PA, XIONG Y, KOBAYASHI M, DU-QUITON J, HRUSHESKY WJ. Daily coordination of cancer growth and circadian clock gene expression. Breast Cancer Res Treat 2005;91:47-60.
103. MAHMOUD F, SARHILL N, MAZURCZAK MA. The therapeutic application of melatonin in supportive care and palliative medicine. Am J Hosp Palliat Care 2005; 22:295-309.
104. KOS-KUDLA B, OSTROWSKA Z, MAREK B et al. Circadian rhythm of melatonin in postmenopausal asthmatic women with hormone replacement therapy. Neuro Endocrinol Lett 2002; 23:243-248.